drugset / Trial / NCT00661739
A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The aim of the study is to establish a feasible combination of bendamustine and paclitaxel in a weekly schedule. The two agents have different toxicity profiles and are well tolerated when given in a weekly fashion. The combination might be of special interest for elderly patients with hormone insensitive breast cancer
Timeline
- Start
- 2005-07
- Primary completion
- 2010-09
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 50 mg/m2 | — |
| Subject | Bendamustine | Small molecule | 60 mg/m2 | — |
| Subject | Bendamustine | Small molecule | 70 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 60 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 90 mg/m2 | — |